Εxploring these pathways, this study provides a potential avenue for targeted therapies in HCC treatment, potentially disrupting the immunosuppressive mechanisms orchestrated by TIM-1+Breg cells and the HMGB1-TLR2/4-MAPK pathway to counteract HCC progression [103]. The gene discussed is TLR2; the disease is hepatocellular carcinoma.